Navigation Links
Promega - TOP srl Agreement Enables Live Animal Imaging for Cancer Studies
Date:3/9/2010

Promega and TOP srl have combined their industry leading technologies to provide the most sensitive tools for monitoring apoptosis in live mammals, an important biomarker in cancer studies.

Madison, WI (PRWEB) March 9, 2010 -- Promega and TOP srl have combined their industry leading technologies to provide the most sensitive tools for monitoring apoptosis in live mammals, an important biomarker in cancer studies. Under the agreement, the two companies are promoting the VivoGlo™ Caspase 3/7 Substrate for use with transgenic repTOP™ reporter mice. The tools allow the direct visualization and quantification of apoptosis non-invasively in live mice.

The study of apoptosis has generated much insight into the mechanisms of action of cancer over the past 20 years but nearly all studies to date have been performed in cells in culture and not in a more biologically relevant animal model such as mice.

TOP srl has developed a proprietary technology enabling the construction of transgenic animals in which the expression of imaging biomarkers is ubiquitous, tightly regulated, and constant among individual animals. Under the agreement, the transgenic repTOP reporter mice will contain an improved luciferase luc2 gene from Promega. It is now possible to study apoptotic processes in the whole live animal with these reporter mice with the same sensitivity and ease as in cell culture models, exploring physiology and pharmacological effects both spatially in different tissues and temporally. “We are pleased to be collaborating with Promega on the use of our transgenic mice with the VivoGlo Caspase 3/7 Substrate for studying apoptosis in vivo. The synergy of the two technologies is going to dramatically improve preclinical research for instance in oncology” said Paolo Ciana, PhD, Vice-President at TOP srl.

About Promega
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 14 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

About TOP srl
TOP srl is a leading company in the production of transgenic reporter mice for the application of in vivo imaging to drug discovery and development, basic research, and toxicology. TOP srl was founded in 2006 by Prof. Adriana Maggi and Dr. Paolo Ciana, of the University of Milan, is backed by the Next Fund of Finlombarda Gestioni SGR, and is based in Lodi, in Northern Italy. For more information, please visit the company’s website at www.top-mice.com

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3441444.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD
2. Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories CRINONE(R) Progesterone Gel Product Line
3. Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 60,800 Square Foot Medical Office Building in Mount Pleasant, South Carolina
4. TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company
5. Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 60,300 Square Foot Medical Office Building in Sugar Land, Texas
6. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
7. Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 260,500 Square Foot Medical Office Portfolio in Indiana
8. UCSF enters drug discovery agreement with Genentech
9. UCSF Enters Drug Discovery Agreement with Genentech
10. MedCath Enters Definitive Agreement To Sell Heart Hospital of Austin
11. Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Lacombe Medical Office Building Near New Orleans
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Promega - TOP srl Agreement Enables Live Animal Imaging for Cancer Studies
(Date:4/24/2017)... ... April 24, 2017 , ... ... individuals with HIV because it is not known to have significant interactions with ... effects to both lower cholesterol levels and dampen inflammation in the bloodstream. , ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the ... for lab operators and management to assess these processes with a critical eye—particularly ... unnecessary actions. , Created with the help of both internal and external ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Reflections of God’s Work”: ... “Reflections of God’s Work” is the creation of published author, Jerri Broglin, a survivor ... , “I believe this a great eye-opener for those searching for answers, as ...
(Date:4/24/2017)... ... April 24, 2017 , ... Miami Periodontist ... 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant Dentistry held ... its annual Global Symposium at the Fontainebleau Hotel located in Miami Beach, FL. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda ... generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today announced ... device as the product advances towards regulatory and clinical phases. , "This is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: